Abstracts Archive - Page 2380 of 2425 - ACR Meeting Abstracts

Abstract Number: 615 • 2012 ACR/ARHP Annual Meeting
Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Michelle Petri¹, Ronald F. van Vollenhoven², Roger A. Levy³, Sandra V. Navarra⁴, Ricard Cervera⁵, Z. John Zhong⁶, William W. Freimuth⁶ and Jill P. Buyon⁷, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Karolinska University Hospital, Stockholm, Sweden, ³Medicine, Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil, ⁴University of Santo Tomas Hospital, Manila, Philippines, ⁵Hospital Clinic, Barcelona, Spain, ⁶Human Genome Sciences, Inc., Rockville, MD, ⁷Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Identification and validation of potential serologic biomarkers of clinically meaningful SLE flare are major unmet medical needs in clinical practice and trials. The purpose…
Abstract Number: 616 • 2012 ACR/ARHP Annual Meeting
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Wendy Cai¹, Cecil Chen¹, Z. John Zhong¹, William W. Freimuth¹, William Lewis² and David Subich³, ¹Human Genome Sciences, Inc., Rockville, MD, ²Covance Clinical Research Unit, Inc., Dallas, TX, ³Covance Clinical Research Unit, Inc., Daytona Beach, FL
Background/Purpose: Belimumab is a recombinant, human Ig-G1λ monoclonal antibody that binds and antagonizes the biological activity of soluble B-lymphocyte stimulator protein, a member of the…
Abstract Number: 617 • 2012 ACR/ARHP Annual Meeting
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels Reflect Organ Damage in Systemic Lupus Erythematosus
Helena Enocsson¹, Jonas Wetterö², Thomas Skogh³ and Christopher Sjöwall⁴, ¹Deparment of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden, ²Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Deparment of clinical and experimental medicine, Linköping University, Linköping, Sweden, ⁴Deparment of clinical and experimental medicine, Linkoping University, Linkoping, Sweden
Background/Purpose: Disease activity assessment in systemic lupus erythematosus (SLE) remains a challenge due to lack of reliable biomarkers and disease heterogeneity. Ongoing tissue inflammation can…
Abstract Number: 618 • 2012 ACR/ARHP Annual Meeting
BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year
Eric Zollars¹, Hong Fang², Jadwiga Bienkowska³, Norm Allaire³, Susan Kalled³ and Michelle Petri², ¹Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Biogen Idec Inc., Cambridge, MA
Background/Purpose: The search for a marker of SLE disease activity has included inflammatory markers, chemokines and gene signatures. We explored the ability of the BAFF…
Abstract Number: 619 • 2012 ACR/ARHP Annual Meeting
Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Felipe Andrade¹, Ehtisham Akhter², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Serum levels of chemokines have been previously used as downstream markers of the interferon (IFN) pathway in SLE. CXCL2 (GROB) and CXCL10 (IP-10) have…
Abstract Number: 620 • 2012 ACR/ARHP Annual Meeting
Development of A Quantitative PCR Method to Determine Interferon Signature Metric Status in SLE Patients: Distribution and Clinical & Serological Associations in Two Lupus Clinical Trials
Bruce C. Richardson¹, William P. Kennedy², John C. Davis Jr.², R. Maciuca², A. Morimoto², J. M. McBride², Alexander R. Abbas², Timothy W. Behrens² and Michael J. Townsend³, ¹Internal Medicine, University of Michigan, Ann Arbor, MI, ²Genentech, Inc, South San Francisco, CA, ³Genentech, South San Francisco, CA
Background/Purpose: Elevated and coordinated expression of multiple Interferon-regulated genes (IRGs) in peripheral blood cells is present in most systemic lupus erythematosus (SLE) patients. Here we…
Abstract Number: 621 • 2012 ACR/ARHP Annual Meeting
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Thomas J. A. Lehman¹, Emily Baird², Anusha Ramanathan³, Risa Alperin³, Emma J. MacDermott³, Alexa B. Adams³, Laura V. Barinstein³ and Lakshmi N. Moorthy⁴, ¹Chief Div Ped Rheum PTD, Hosp for Special Surgery, New York, NY, ²Hospital for Special Surgery, NY, ³Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Pediatric Rheumatology, Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ
Prolonged improvement of systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Background/Purpose: We report sustained improvement in 15 patients with corticosteroid dependent SLE…
Abstract Number: 622 • 2012 ACR/ARHP Annual Meeting
Headache in Systemic Lupus Erythematosus (SLE): Results From a Prospective, International, Inception Cohort Study
John G. Hanly¹ and Systemic Lupus International Collaborating Clincs², ¹Division of Rheumatology, Dalhousie University and Capital Health, Halifax, NS, Canada, ²(SLICC), Canada
Background/Purpose: Headache is common in SLE patients and in the general population. We examined the frequency, characteristics and attribution of headaches in a large, prospective,…
Abstract Number: 623 • 2012 ACR/ARHP Annual Meeting
Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus
Ben Parker¹, Awal Zaki², M. Yvonne Alexander³ and Ian N. Bruce⁴, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ²Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ³Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of clinical and subclinical cardiovascular disease (CVD) including endothelial dysfunction, in part due to…
Abstract Number: 624 • 2012 ACR/ARHP Annual Meeting
Excess Health Care Utilization Prior to Diagnosis of Systemic Lupus Erythematosus in England
Amy Steffey¹, Trung N. Tran¹, Jie Li¹ and Herve Caspard², ¹Epidemiology, Clinical Development, MedImmune, Gaithersburg, MD, ²Epidemiology, Clinical Development, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease resulting in significant excess morbidity and health care utilization. Since time of disease onset is…
Abstract Number: 625 • 2012 ACR/ARHP Annual Meeting
Control of Hypertension and Hypercholesterolemia Is Not Associated with a Decreased Rate of Atherosclerotic Vascular Events in Patients with Systemic Lupus Erythematosus
Joanna Ueng¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. It has been shown that patients with SLE are at a higher…
Abstract Number: 626 • 2012 ACR/ARHP Annual Meeting
The Interferon Alpha Gene Signature Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium (CAC) or Carotid Intima-Media Thickness (IMT) in Systemic Lupus Erythematosus (SLE)
Adnan Kiani¹, Hong Fang¹, Jie Xu², Ehtisham Akhter³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis is the major cause of late mortality in SLE. Interferon alpha plays a role in atherosclerosis by deleting endothelial progenitor cells and…
Abstract Number: 627 • 2012 ACR/ARHP Annual Meeting
Zostavax Vaccine Is Safe in Lupus Patients with Low Disease Activity
Eliza F. Chakarvarty¹, Joel M. Guthridge², Joan T. Merrill³, Abigail Cogman², Tiny Powe¹, Virginia C. Roberts⁴ and Judith A. James⁵, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis Immunology, OMRF, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The Zostavax vaccine was FDA approved in 2006 for the prevention of herpes zoster in healthy adults over age 50. Because it is…
Abstract Number: 628 • 2012 ACR/ARHP Annual Meeting
Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion
Ki-Jo Kim¹, In-Woon Baek², Chong-Hyeun Yoon³, Wan-Uk Kim² and Chul-Soo Cho⁴, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ²Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁴Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: The heparin sulphate proteoglycans (HSPGs) in the glomerular basement membrane (GBM) play an important role in the charge-selective permeability of the glomerular filter. The…
Abstract Number: 629 • 2012 ACR/ARHP Annual Meeting
Inflammatory Biomarkers of Atherosclerosis and Oxidative Stress Are Associated with Disease Flare in SLE
Maureen A. McMahon¹, Jennifer M. Grossman¹, Brian Skaggs², Elaine Lourenco², Cheryl Lee¹, Lori Sahakian³, John FitzGerald⁴, Christina Charles-Schoeman⁵, Alan H. Gorn⁶, George A. Karpouzas⁷, Michael H. Weisman⁸, Daniel J. Wallace⁹, Weiling Chen¹ and Bevra H. Hahn⁶, ¹Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine/Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³Division of Rheumatology, Department of Medicine,, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵University of California, Los Angeles, CA, ⁶Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁷Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ⁸Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Although our current serologic measures of disease activity are useful for predicting flare in some patients, other patients experience disease flare in the absence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].